CONSULTANT HAEMATOLOGIST
Dr Pasquale Fedele
MBBS (Hons) PhD FRACP FRCPA
Dr Pasquale Fedele is a clinical and laboratory haematologist at Monash Health and is a fellow of both the Royal Australasian College of Physicians (RACP) and Royal College of Pathologists of Australasia (RCPA).
Dr Fedele completed his undergraduate training in medicine at Monash University. He then completed haematology training at Monash Health and The Alfred Hospital before undertaking a PhD at the Walter & Eliza Hall Institute of Medical Research/Melbourne University in the role of transcription factors in multiple myeloma.
Practice Interests
Dr Fedele is passionate about improving care for patients with haematological diseases. He is actively involved in clinical and translational research as principal investigator on multiple trials in leukaemia, multiple myeloma genomics and cancer survivorship and has numerous publications in international peer review journals.
Dr Fedele consults out of St John of God Berwick and Monash Specialist Centre Clayton. He has an interest in both malignant and non-malignant haematology and is happy to take referrals across the full scope of blood disorders.
Practice Locations
Dr Pasquale Fedele consults privately out of St John of God Berwick and Monash Specialist Centre Clayton.
TeleHealth appointments are available.
St John of God Hospital Consulting Suites
Ground Floor
75 Kangan Drive
Berwick VIC 3806
Tel: 03 5910 6100
Fax: 03 5910 6101
Monash Specialist Centre
Suite 10
212-220 Clayton Rd
Clayton VIC 3168
Tel: 03 5910 6100
Fax: 03 5910 6101
Hospital Accreditation
Clinical Interests Include:
Updated: September 2025
Extended Profile
Dr Pasquale Fedele
– Key Research, Journal & Book Publications, Presentations &/or Awards
Selected Journal Publications
- Salvaris R, Fedele PL. Targeted Therapy in Acute Lymphoblastic Leukaemia. J Pers Med. 2021 Jul 25;11(8):715
- Fedele PL, Liao Y, Gong JN, Yao Y, van Delft MF, Low MSY, Tai L, Herold MJ, Jackson JT, Teh CE, Tan T, O’Reilly LA, Tellier J, Grigoriadis G, Huang DCS, Shi W, Nutt SL, Willis SN. The transcription factor IRF4 represses pro-apoptotic BMF and BIM to licence Multiple Myeloma survival. Leukemia. 2021 Jul;35(7):2114-2118.
- Teh CE, Gong JN, Segal D, Tan T, Vandenberg CJ, Fedele PL, Low MSY, Grigoriadis G, Harrison SJ, Strasser A, Roberts AW, Huang DCS, Nolan GP, Gray DHD, Ko ME. Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell Death Differ. 2020;27(7):2217-2233
- Tedjaseputra A, Gilbertson M, Low M, Fedele PL, Kumar B, Simpson I, Grigoriadis G, Shortt J, Opat S, Gregory GP. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian, single-centre experience. Intern Med J. 2020 Jul 1 [Online ahead of print].
- Low MSY, Brodie EJ, Fedele PL, Liao Y, Grigoriadis G, Strasser A, Kallies A, Willis SN, Tellier J, Shi W, Gabriel S, O’Donnell K, Pitt C, Nutt SL, Tarlinton D. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis. Cell Reports. 2019; 29(9):2634-2645.
- Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. British Journal of Haematology. 2019;184(4):679-682
- Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, Gong JN, Huntington ND, Shi W, Huang DCS, Grigoriadis G, Tellier J, Nutt SL. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018; 132(20):2166-2178.
- Trezise S, Karnowski A, Fedele PL, Mithraprabhu S, Liao Y, D’Costa K, Kueh AJ, Hardy MP, Owczarek CM, Herold MJ, Spencer A, Shi W, Willis SN, Nutt SL, Corcoran LM. Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins. Int J Mol Sci. 2018; 19(8): pii: E2161.
- Yuen HLA, Low MSY, Fedele P, Kalff A, Walker P, Bergin K, Coutsouvelis J, Grigoriadis G, Spencer A. DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma. Leukemia & Lymphoma. 2018; 59(12):2842-2846.
- Chee A, Low MS, Vilcassim S, Gregory GP, Gilbertson M, Ratnasingam S, Grigoriadis G, Fedele PL. Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma. British Journal of Haematology. 2018 Sep;182(5):739-741
- Fedele PL, Polizzotto M, Grigoriadis G, Waters N, Comande M, Borosak M, Portbury D, Wood E. Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study. Transfusion. 2016; 56(10):2455-2465.
- Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, Grigoriadis G. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Annals of Hematology. 2016; 95(4):667-8.
- Fedele PL, Choy K, Doery J, Shortt J, Grigoriadis G, Lu ZX. Inter-laboratory discordance of beta-2 microglobulin results: impact on the validity of the international staging system for multiple myeloma. British Journal of Haematology. 2014;166(6):951-953.
- Fedele PL, Avery S, Patil S, Spencer A, Wei A. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia. Internal Medicine Journal. 2014; 44(8):757-763
- Cheah C, Herbert K, ORourke K, Kennedy G, Anupkumar G, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies amongst patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer. 2014; 111(6):1072-1079
